title: [Concomitant therapy with cefmenoxime and cefsulodin for refractory complicated urinary tract infection (especially caused by Pseudomonas aeruginosa)].
abstract: Cefmenoxime (2 g) and cefsulodin (1 g) were given twice daily for 5 days by concomitant intravenous drip infusion (mixed infusion) to 135 patients with complicated urinary tract infection (c-UTI) probably caused by Pseudomonas aeruginosa. The clinical efficacy was evaluated according to the criteria proposed by the UTI committee in Japan. Ninety one subjects met the criteria for c-UTI and were evaluable for drug efficacy. P. aeruginosa was detected in 44 cases (including mixed infection with other organisms). The overall efficacy rate was 73% of the 91 cases; 75% of the 44 cases with P. aeruginosa and 70% in the 47 cases without P. aeruginosa infection. As to bacteriological response, the eradication rate was 91% (105/116) for all cases. By organism, the eradication rate for P. aeruginosa, Serratia spp. and Citrobacter spp. were 82 (36/44), 100 (12/12) and 100% (10/10), respectively. The eradication rate for gram-negative rods was 93% (99/107). Twenty-three strains appeared after treatment, and the majority of them (13) were yeast-like organisms. There was only one strain of P. aeruginosa. As for side effects, eruption was found in 2 cases. Cefmenoxime and cefsulodin were administered concomitantly to patients with c-UTI which was suspected to be caused by P. aeruginosa. The high overall efficacy rate of about 70% on the average was obtained regardless of the causative organism and disease state. The eradication rate of as high as about 90% was obtained excluding Enterococcus faecalis. Neither severe side effects nor abnormal laboratory values were found. It appeared, therefore, that this dosage regimen was useful for the treatment of refractory complicated urinary tract infection.
authors.forename: J
authors.initials: J
authors.lastname: Ishigami
authors.forename: A
authors.initials: A
authors.lastname: Fujii
authors.forename: M
authors.initials: M
authors.lastname: Harada
authors.forename: S
authors.initials: S
authors.lastname: Arakawa
authors.forename: K
authors.initials: K
authors.lastname: Umezu
authors.forename: G
authors.initials: G
authors.lastname: Kawabata
authors.forename: N
authors.initials: N
authors.lastname: Kataoka
authors.forename: S
authors.initials: S
authors.lastname: Kamidono
authors.forename: S
authors.initials: S
authors.lastname: Miyazaki
authors.forename: N
authors.initials: N
authors.lastname: Takasaki
mesh_terms: D000892:Anti-Infective Agents, Urinary / Q000008:administration & dosage*; D015281:Cefmenoxime; D002439:Cefotaxime / Q000008:administration & dosage / Q000031:analogs & derivatives*; D002441:Cefsulodin / Q000008:administration & dosage*; D002908:Chronic Disease; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006801:Humans; D011552:Pseudomonas Infections / Q000188:drug therapy*; D014552:Urinary Tract Infections / Q000188:drug therapy*
chemical_list: D000892:Anti-Infective Agents, Urinary; D015281:Cefmenoxime; D002439:Cefotaxime; D002441:Cefsulodin